Collumbotai Biotech (06990) rose more than 7% in early trading. As of press release, it had risen 6.61% to HK$175.9, with a turnover of HK$237.47,800.
The Zhitong Finance App learned that Columbite Biotech (06990) once again rose more than 7% in early trading. As of press release, it had risen 6.61% to HK$175.9, with a turnover of HK$237.47,800.
According to the news, Colon Biotech plans to place 3,648,600 shares to no less than six undertakers at a price of HK$150, a discount of about 6.83% from the closing price of HK$161 on May 7, with a net proceeds of approximately HK$540.5 million. The company will also place 4.423,900 shares at the same price of HK$150 per share to the controlling shareholder Colon Pharmaceuticals, with a net proceeds of approximately HK$662 million. Colon Pharmaceuticals will maintain a shareholding ratio of around 54.8% in the company.
The company plans to use the net proceeds from the placement process for R&D, clinical trials, registration, manufacturing and commercialization of core products and other products; enhance internal R&D technical capabilities, strengthen external cooperation and expand the product pipeline portfolio; supplement working capital and use for general corporate purposes.